BDRX vs SIGA vs NUVB

For growth investors, Nuvation Bio Inc.

(NUVB) is the stronger pick with 699. 0% revenue growth year-over-year, versus -31. 8% for SIGA Technologies, Inc. (SIGA). SIGA Technologies, Inc. (SIGA) offers the better valuation at 14. 5x trailing P/E (2. 8x forward), making it the more compelling value choice. Analysts rate SIGA Technologies, Inc. (SIGA) a "Buy" — based on 1 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, SIGA Technologies, Inc.

(SIGA) delivered a total return of +7. 9%, compared to -100. 0% for Biodexa Pharmaceuticals Plc (BDRX). Over 10 years, the gap is even starker: SIGA returned +772. 1% versus BDRX's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), SIGA Technologies, Inc.

(SIGA) is the lower-risk stock at 1. 09β versus Nuvation Bio Inc. 's 1. 97β — meaning NUVB is approximately 80% more volatile than SIGA relative to the S&P 500. On balance sheet safety, SIGA Technologies, Inc. (SIGA) carries a lower debt/equity ratio of 0% versus 3% for Nuvation Bio Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Nuvation Bio Inc.

(NUVB) is pulling ahead at 699. 0% versus -31. 8% for SIGA Technologies, Inc. (SIGA). On earnings-per-share growth, the picture is similar: Biodexa Pharmaceuticals Plc grew EPS 100. 0% year-over-year, compared to -60. 2% for SIGA Technologies, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

SIGA Technologies, Inc.

(SIGA) is the more profitable company, earning 24. 6% net margin versus -325. 3% for Nuvation Bio Inc. — meaning it keeps 24. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SIGA leads at 25. 1% versus -338. 7% for NUVB. At the gross margin level — before operating expenses — NUVB leads at 86. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

In this comparison, SIGA (12.

5% yield) pays a dividend. BDRX, NUVB do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, SIGA Technologies, Inc.

(SIGA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 09), 12. 5% yield, +772. 1% 10Y return). Nuvation Bio Inc. (NUVB) carries a higher beta of 1. 97 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (SIGA: +772. 1%, NUVB: -52. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: BDRX is a small-cap quality compounder stock; SIGA is a small-cap deep-value stock; NUVB is a small-cap high-growth stock. SIGA pays a dividend while BDRX, NUVB do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.